Bio-rad Laboratories, Inc. income statement

In fiscal 2025, Bio-rad Laboratories, Inc. reported revenue of $2.58bn, up 0.7% on the year before, operating income of $47.2m (a 1.8% margin) and net income of $760m, or $27.85 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Bio-rad Laboratories, Inc.: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	1,784	1,927	2,074	2,069	2,133	2,175	2,019	2,068	2,160	2,289	2,312	2,546	2,923	2,802	2,671	2,567	2,583	2,589
Cost of revenue	—	—	—	—	—	—	—	930	972	1,066	1,055	1,108	1,284	1,235	1,244	1,188	1,243	1,246
Gross profit	1,000	1,091	1,179	1,155	1,178	1,179	1,122	1,138	1,188	1,223	1,257	1,438	1,638	1,567	1,427	1,379	1,340	1,344
Research and development	164	172	178	209	211	220	193	206	250	199	203	218	261	257	247	296	276	266
Selling, general and administrative	601	635	696	682	798	808	762	815	807	835	825	799	877	828	842	814	844	852
Operating income	231	284	305	264	169	150	167	56	119	−103	230	421	500	483	338	269	47	53
Interest expense	47	64	53	51	61	22	22	23	23	24	23	22	2	38	49	49	49	49
Provision for credit losses	—	—	—	—	—	—	—	—	—	—	—	0	0	8	0	0	1	—
Income before tax	186	220	246	230	112	132	146	42	98	513	2,261	4,918	5,449	−4,704	−850	−2,343	996	350
Income tax	37	33	67	64	35	43	37	16	−24	147	502	1,104	1,195	−1,077	−213	−498	236	128
Net income	145	185	179	165	78	89	109	26	122	366	1,759	3,814	4,254	−3,628	−637	−1,844	760	222
Diluted EPS	$5.20	$6.59	$6.29	$5.78	$2.69	$3.05	$3.71	$0.88	$4.07	$12.10	$58.27	$126.47	$140.83	−$121.79	−$21.82	−$65.36	$27.85	$8.26
Diluted shares (average)	28m	28m	28m	29m	29m	29m	29m	30m	30m	30m	30m	30m	30m	30m	29m	28m	27m	27m
EBITDA	333	393	426	395	317	300	299	199	268	35	364	560	638	620	484	421	213	—

US$ millions unless shown otherwise. Fiscal quarters.

Bio-rad Laboratories, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	650	668	585	652	653	693	592	651
Cost of revenue	294	326	279	306	310	348	283	305
Gross profit	356	342	306	345	343	345	309	346
Research and development	91	80	74	61	71	70	63	61
Selling, general and administrative	200	204	209	208	207	221	212	212
Operating income	65	58	24	77	65	−119	34	73
Interest expense	12	12	12	13	12	12	12	12
Income before tax	862	−909	83	414	−431	929	−690	542
Income tax	208	−193	19	96	−89	209	−163	171
Net income	653	−716	64	318	−342	720	−527	371
Diluted EPS	$23.34	−$25.57	$2.29	$11.67	−$12.70	$26.39	−$19.55	$13.85

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BIO vs FTRE BIO vs MEDP BIO vs QGEN

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bio-rad Laboratories, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bio-rad Laboratories, Inc.